LivaNova PLC reported its fourth-quarter and full-year 2024 financial results, demonstrating strong revenue growth and significantly improved cash generation. For the full year 2024, total net revenue increased 8.7% to $1,253.4 million, or 10.1% organically, compared to $1,153.5 million in 2023. Adjusted diluted earnings per share for 2024 were $3.38, up from $2.80 in the prior year.
The Cardiopulmonary segment's full-year revenue increased 13.1% to $683.5 million, driven by Essenz Perfusion System sales and strong consumables demand. Neuromodulation revenue grew 6.6% to $554.2 million, with growth in the Rest of World and U.S. regions. Adjusted operating income for 2024 was $239.2 million, a significant increase from $169.3 million in 2023.
For full-year 2025, LivaNova expects revenue to grow between 5.0% and 6.0% on a constant-currency basis, or 6.0% to 7.0% organically. Adjusted diluted earnings per share are projected in the range of $3.65 to $3.75, and adjusted free cash flow is estimated between $135 million and $155 million. The Italian Supreme Court will hold a public hearing on February 26, 2025, regarding the SNIA litigation, with a decision expected in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.